GeneTex
United States (US)

Cytohesin 1 antibody [CYT1-82]

Cat No. GTX12425

Host Mouse
Clonality Monoclonal
Clone Name CYT1-82
Isotype IgG1
Application WB, ICC/IF, ELISA
Reactivity Human
APPLICATION

Application Note

*Optimal dilutions/concentrations should be determined by the researcher.
Application Dilution
WB 2-4?μg/ml
ICC/IF Assay dependent
ELISA Assay dependent
Not tested in other applications.

Calculated MW

46 kDa. ( Note )

Positive Control

Raji
PROPERTIES

Form

Liquid

Buffer

0.01M PBS pH7.4, 15 mM sodium azide

Storage

Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.

Concentration

~2mg/ml

Antigen Species

Human

Immunogen

recombinant human cytohesin-1.

Purification

Purified immunoglobulin

Conjugation

Unconjugated

Note

For In vitro laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
TARGET

Background

ARFs (ADP ribosylation factors) are GTP-binding proteins (20 kDa), which catalyze ADP-ribosylation of the alpha-subunit of the adenylyl cyclase-stimulatory G protein. ARFs are active when GTP, but not GDP or ATP, is bound. Hydrolysis of bound GTP to GDP with assistance of GTPase-activating protein results in inactive ARF-GDP. Conversion of ARF-GDP to ARFGTP is promoted by GEP (guanine-exchange protein). Inhibition of GEP activity by brefeldin A (BFA), a fungal metabolite that reversibly causes apparent disintegration of Golgi in cells, has been reported. ARFs have been shown to regulate various aspects of vesicular trafficking pathways in mammalian cells, including endocytosis, phagocytosis, secretion, and endoplasmic reticulum protein transport and budding of transport vesicles from Golgi in both anterograde and retrograde classes (class I: ARFs 1, 2 and 3, class II: ARFs 4 and 5, and class III: ARF 6), based on size, gene structure and sequence identity. The ARF-GEP family, referred to as 'cytohesins', include cytohesin 1, ARNO (ARF nucleotide binding site opener, also called cytohesin 2), and GRP1 (general receptor for phosphoinositides-1, also known as cytohesin 3 or ARNO3). The members of this family are characterized by an N-terminal coiled-coil domain of 40 amino acids, a Ptdlns (3,4,5)P3-binding C-terminal PH (pleckstrin homology) domain, and a central Sec7 domain. Sec7 is a conserved catalytic domain of approximately 200 amino acids, which stimulates the exchange of GDP to GTP on members of the ARF family of GTPases. The PH domain, by interacting with phospholipids, is believed to be responsible for association of cytoplasm with membranes. Cytohesin 1, the protein product of the B2-1 gene, is a 47 kDa protein. It is abundant in cells of the immune system and is expressed at high levels in natural killer cells and peripheral T lymphocytes, and also expressed at very low levels in purified monocytes and several cultured cell lines. Cytohesin 1 contains two structural motifs: a large central Sec7 domain (200 amino acids) and a carboxy-terminal PH domain (100 amino acids). Overexpression of a cytohesin 1 Sec7 domain fusion protein in Jurkat cells markedly increases cell binding to the extracellular domain of ICAM-1, and direct interaction of the Sec7 domain with the cytoplasmic domain of beta1 integrin was demonstrated in vitro. Cytohesin 1 acts as a GEP that accelerates GTP(yS) and GDP binding to purified native ARF3, and induces ARF binding to Golgi membranes via a mechanism insensitive to BFA. Via its PH domain, cytohesin 1 can bind the lipid product of PI3-Kinase activation, a binding that is visualized through the recruitment of cytohesin-1 to the plasma membrane. Also, granulocytic differentiation of HL-60 cells induced by cAMP results in a marked increase of the levels of endogenous cytohesin 1.
Show More +

Database

Package List Price ($)
$ 289